Becton Dickinson sees strong Q3

Becton, Dickinson ($BDX) reported revenues of more than $2 billion for the third fiscal quarter ending June 30, representing an increase of 10% from the prior-year period and beating analyst expectations, as Reuters notes.

BD also raised its previous guidance for reported diluted earnings per share from continuing operations for the fiscal year from $5.55-$5.65 to $5.65-$5.70.

The company saw good results in all three of its segments. The BD Medical segment had worldwide quarterly revenues of $1.045 billion, representing an increase of 10.5% versus the prior-year period. Its diagnostics segment enjoyed worldwide revenues of $631 million, representing an increase of 9.6% compared with the prior-year period. Meanwhile, the company's biosciences segment had worldwide revenues of $338 million, representing an increase of 9.3% versus the prior-year period.

The good financial news comes a few days after the company announced it had elected Vincent Forlenza as president and CEO effective October 1. Current Chairman and CEO Edward Ludwig will serve as executive chairman of the board through June 2012. BD also last week bought Sweden's Carmel Pharma, which manufactures the PhaSeal system for the safe handling of hazardous drugs that are packaged in vials. The acquisition is expected to close by the end of BD's current fiscal year 2011; no financial terms were disclosed.

- see the BD release
- check out more from Reuters

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.